Cargando…

Management of hepatocellular carcinoma from diagnosis in routine clinical practice

AIM: To assess real-world management of patients diagnosed with hepatocellular carcinoma (HCC) within an integrated delivery network. MATERIALS & METHODS: A retrospective cohort analysis of adults newly diagnosed with HCC from January 2014 to March 2019. Overall survival and treatment journey we...

Descripción completa

Detalles Bibliográficos
Autores principales: Lokhandwala, Tasneem, Aly, Abdalla, Farrelly, Eileen, Willey, Joanne P, Lamerato, Lois E, Healey, Marcus, Coutinho, Anna D, Seal, Brian S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064261/
https://www.ncbi.nlm.nih.gov/pubmed/37009420
http://dx.doi.org/10.2217/hep-2021-0011
_version_ 1785017865736290304
author Lokhandwala, Tasneem
Aly, Abdalla
Farrelly, Eileen
Willey, Joanne P
Lamerato, Lois E
Healey, Marcus
Coutinho, Anna D
Seal, Brian S
author_facet Lokhandwala, Tasneem
Aly, Abdalla
Farrelly, Eileen
Willey, Joanne P
Lamerato, Lois E
Healey, Marcus
Coutinho, Anna D
Seal, Brian S
author_sort Lokhandwala, Tasneem
collection PubMed
description AIM: To assess real-world management of patients diagnosed with hepatocellular carcinoma (HCC) within an integrated delivery network. MATERIALS & METHODS: A retrospective cohort analysis of adults newly diagnosed with HCC from January 2014 to March 2019. Overall survival and treatment journey were assessed over the entire available follow-up period per patient. RESULTS: Of the 462 patients, 85% had ≥1 treatment. The 24-month overall survival rate (95% CI) from first treatment was 77% (72–82%). Majority of Child-Pugh class A (71%) and B (60%) patients received locoregional therapy first. Half (53.6%) of the patients with liver transplantation first were Child-Pugh class C patients. Sorafenib was the predominant systemic therapy. CONCLUSION: This integrated delivery network data analysis offers a comprehensive insight into the real-world management of HCC.
format Online
Article
Text
id pubmed-10064261
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Future Medicine Ltd
record_format MEDLINE/PubMed
spelling pubmed-100642612023-04-01 Management of hepatocellular carcinoma from diagnosis in routine clinical practice Lokhandwala, Tasneem Aly, Abdalla Farrelly, Eileen Willey, Joanne P Lamerato, Lois E Healey, Marcus Coutinho, Anna D Seal, Brian S Hepat Oncol Short Communication AIM: To assess real-world management of patients diagnosed with hepatocellular carcinoma (HCC) within an integrated delivery network. MATERIALS & METHODS: A retrospective cohort analysis of adults newly diagnosed with HCC from January 2014 to March 2019. Overall survival and treatment journey were assessed over the entire available follow-up period per patient. RESULTS: Of the 462 patients, 85% had ≥1 treatment. The 24-month overall survival rate (95% CI) from first treatment was 77% (72–82%). Majority of Child-Pugh class A (71%) and B (60%) patients received locoregional therapy first. Half (53.6%) of the patients with liver transplantation first were Child-Pugh class C patients. Sorafenib was the predominant systemic therapy. CONCLUSION: This integrated delivery network data analysis offers a comprehensive insight into the real-world management of HCC. Future Medicine Ltd 2023-03-27 /pmc/articles/PMC10064261/ /pubmed/37009420 http://dx.doi.org/10.2217/hep-2021-0011 Text en © 2023 AstraZeneca PLC https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Short Communication
Lokhandwala, Tasneem
Aly, Abdalla
Farrelly, Eileen
Willey, Joanne P
Lamerato, Lois E
Healey, Marcus
Coutinho, Anna D
Seal, Brian S
Management of hepatocellular carcinoma from diagnosis in routine clinical practice
title Management of hepatocellular carcinoma from diagnosis in routine clinical practice
title_full Management of hepatocellular carcinoma from diagnosis in routine clinical practice
title_fullStr Management of hepatocellular carcinoma from diagnosis in routine clinical practice
title_full_unstemmed Management of hepatocellular carcinoma from diagnosis in routine clinical practice
title_short Management of hepatocellular carcinoma from diagnosis in routine clinical practice
title_sort management of hepatocellular carcinoma from diagnosis in routine clinical practice
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064261/
https://www.ncbi.nlm.nih.gov/pubmed/37009420
http://dx.doi.org/10.2217/hep-2021-0011
work_keys_str_mv AT lokhandwalatasneem managementofhepatocellularcarcinomafromdiagnosisinroutineclinicalpractice
AT alyabdalla managementofhepatocellularcarcinomafromdiagnosisinroutineclinicalpractice
AT farrellyeileen managementofhepatocellularcarcinomafromdiagnosisinroutineclinicalpractice
AT willeyjoannep managementofhepatocellularcarcinomafromdiagnosisinroutineclinicalpractice
AT lameratoloise managementofhepatocellularcarcinomafromdiagnosisinroutineclinicalpractice
AT healeymarcus managementofhepatocellularcarcinomafromdiagnosisinroutineclinicalpractice
AT coutinhoannad managementofhepatocellularcarcinomafromdiagnosisinroutineclinicalpractice
AT sealbrians managementofhepatocellularcarcinomafromdiagnosisinroutineclinicalpractice